Primary source: Cancellation of Notified Cosmetic Products
The report includes specific causality verification processes conducted by the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) which determines safety profiles for registered drugs.
This report is crucial for informing healthcare professionals and the public about drug safety and the regulatory actions that NPRA may take, such as updating product information or restricting product use.
Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.
The NPRA issued an annual report outlining their activities in monitoring adverse drug reactions (ADRs) and adverse events following immunization (AEFIs) in Malaysia, providing insights into drug safety and regulatory measures.
What changed: The report includes specific causality verification processes conducted by the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) which determines safety profiles for registered drugs.
Why it matters: This report is crucial for informing healthcare professionals and the public about drug safety and the regulatory actions that NPRA may take, such as updating product information or restricting product use.
Practical implication: Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.
Published from the regulator source ingestion pipeline after PV impact triage.
Regulatory requirements for daratumumab will need to be reviewed in light of the orphan designation status granted by the EMA.
Healthcare providers must implement a follow-up process for patients with identified cobalt-chrome modular neck components, monitoring for new or unexpected symptoms including pain, stiffness, or instability.
Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
